During the last session, Quoin Pharmaceuticals Ltd ADR (NASDAQ:QNRX)’s traded shares were 0.32 million, with the beta value of the company hitting 1.81. At the end of the trading day, the stock’s price was $0.31, reflecting an intraday gain of 3.20% or $0.01. The 52-week high for the QNRX share is $1.57, that puts it down -406.45 from that peak though still a striking 9.68% gain since the share price plummeted to a 52-week low of $0.28. The company’s market capitalization is $1.56M, and the average trade volume was 5.86 million shares over the past three months.
Quoin Pharmaceuticals Ltd ADR (QNRX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. QNRX has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.43.
Quoin Pharmaceuticals Ltd ADR (NASDAQ:QNRX) trade information
Quoin Pharmaceuticals Ltd ADR (QNRX) registered a 3.20% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 3.20% in intraday trading to $0.31, hitting a weekly high. The stock’s 5-day price performance is -0.29%, and it has moved by -0.39% in 30 days. Based on these gigs, the overall price performance for the year is -79.35%.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -194.79%. While earnings are projected to return 78.42% in 2025, the next five years will return 82.69% per annum.
QNRX Dividends
Quoin Pharmaceuticals Ltd ADR is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Data provided on Apr 30, 2024 indicates that Fidelity NASDAQ Composite Index Fund owns about 95.0 shares. This amounts to just over 0.00 percent of the company’s overall shares, with a $29.0 market value.
